|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphic activities of debrisoquine 4-hydroxylase were suggested to be associated with some complex diseases, such as cancer and Parkinson's disease.
|
11702057 |
2001 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using allele-specific multiplex PCR, we genotyped 186 subjects for CYP2D6 *3, *4, *6, *7, and *8 alleles in order to estimate allelic, genotype and predicted phenotype frequencies in the control and patient groups, and to investigate the possible statistical difference between Parkinson's disease patients (n=41) and healthy controls (n=145).
|
11097352 |
2000 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE).
|
10928584 |
2000 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic variation at the CYP2D6 gene has been reported to be associated with Parkinsons' disease (PD) and Lewy body dementia (LBD), but not with Alzheimer's disease (AD).
|
10071712 |
1999 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined alleles frequency of CYP2D6*3 + apoE4 was significantly higher not only in the PD group (33.3%) but also in patients with parkinsonism (22.3%) compared to control subjects (1.6%).
|
10353349 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whilst an elevated frequency of the CYP2D6*4 allele was found in Parkinson's disease, no such elevations were found in DLB or Alzheimer's disease.
|
10208640 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seventeen mutations occurring alone or in various combination on 14 alleles of CYP2D6 have been identified in patients with sporadic PD.
|
10091614 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This comprehensive study of CYP2D6 mutations demonstrates that other genes or shared environmental exposures account for the familial risk of PD.
|
10435495 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between CYP2D6 genotypes (reported to be associated with the susceptibilities to Parkinson's disease and multisystem atrophy) and the possible susceptibility to neuroleptic malignant syndrome (NMS) and subacute myelo-optico-neuropathy (SMON), we analyzed the CYP2D6 gene by polymerase chain reaction and restriction fragment length polymorphism in Japanese schizophrenia patients with a history of NMS.
|
9892857 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
|
9918130 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although some characteristic patterns of the combined genotypes were observed in both PD patients and controls, a strong association between the heterogeneity of the CYP2D6 gene and PD was not shown by combined genotype analysis.
|
9440484 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data do not support the suggestion that the CYP2D6 gene is related to PD susceptibility in Chinese.
|
9667775 |
1998 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired debrisoquine metabolism resulting from defects in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene has been shown to be associated with the development of Parkinson's disease (PD).
|
9613747 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By contrast with the common occurrence of polymorphism of the CYP2D6 gene (a gene involved with xenobiotic metabolism) in white people, it is very rare in China and is not thought to be a significant factor contributing to Parkinson's disease in Chinese people.
|
9810958 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CYP2D6 B mutation may be involved in pathogenesis of LBV and PD in a dominant-negative manner, or in the linkage disequilibrium of the CYP2D microsatellite to another pathogenic gene locus.
|
9633694 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, reports of associations between alleles of the CYP2D6 locus (nearby on 22q13) and IPD, although inconsistent, indicated that an IPD susceptibility locus might be in strong linkage disequilibrium with CYP2D6.
|
9630632 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As yet, there is no conclusive evidence to suggest that CYP2D6 polymorphisms confer susceptibility to PD.
|
9539332 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results provide evidence to suggest that there may be an unidentified locus for susceptibility to Parkinson's disease that is in linkage disequilibrium with dinucleotide repeat markers mapping near CYP2D6 on ch22q13.
|
9189044 |
1997 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed a case-control study to investigate the association of the poor metaboliser genotype of the cytochrome P450 2D6 gene with Parkinson's disease (PD).
|
9455978 |
1997 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed a genetic risk factor of Alzheimer's disease (AD), apolipoprotein E, hypothesized to be linked to NFT formation, and a genetic risk factor of Parkinson's disease (PD), CYP2D6 mutation, linked to slower metabolism of exogenous toxins, in Chamorro, Guam individuals with and without PDC.
|
8797479 |
1996 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast with the results from genotyping studies conducted among patients with an older age at onset, there were no significant differences in CYP2D6 allelic frequencies between young-onset PD cases and controls.
|
8710083 |
1996 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results argue against a significant role of the CYP2D6 gene in the aetiology of sporadic and familial idiopathic parkinsonism in this patient population.
|
8937349 |
1996 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that CYP2D6, CYP1A2 and, to a lesser extent CYP3A4, may have a role in protecting against Parkinson's disease induced by MPTP and other potential environmental neurotoxins.
|
8627546 |
1996 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, other hypotheses have been suggested: impairment of neuronal CYP 2D6 expression, transient modification of CYP 2D6 phenotype, or linkage of CYP2D6 gene to the candidate gene locus directly involved in IPD.
|
8726540 |
1996 |